The Sequence-Dependent Cytotoxic Effect of Trastuzumab in Combination With 5-Fluorouracil or Cisplatin on Gastric Cancer Cell Lines

REFERENCES

• Karpeh, M.S.; Kelsen, D.P.; Tepper, J.E. Cancer of the stomach. In Cancer: Principles and Practice of Oncology. V.T. DeVita, Jr.; S. Hellman; S.A. Rosenberg (eds.). Philadelphia, PA: Lippincott, 2001, 1092–1126.
   Google Scholar
• Van Cutsem, E.; Kang, Y.; Chung, H.; Shen, L.; Sawaki, A.; Lordick, F.; Hill J.; Lehle, M.; Feyereislova, A.; Bang, Y. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009, 27, 18s (suppl; abstr LBA4509).
   Google Scholar
• Roukos, D.H. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 2009 (Oct 20). [Epub ahead of print].
   Web of Science ®Google Scholar
• Gong, S.J.; Jin, C.J.; Rha, S.Y.; Chung, H.C. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004, 214(2), 215–224.
   PubMed Web of Science ®Google Scholar
• Matsui, Y.; Inomata, M.; Tojigamori, M.; Sonoda, K.; Shiraishi, N.; Kitano, S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27(3), 681–685.
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi, K.; Sekiguchi, F.; Yasuno, H. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59(6), 795–805.
   PubMed Web of Science ®Google Scholar
• Kim, S.Y.; Kim, H.P.; Kim, Y.J.; Oh do, Y.; Im, S.A.; Lee, D.; Jong, H.S.; Kim, T.Y.; Bang, Y.J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32(1), 89–95.
   PubMed Web of Science ®Google Scholar
• Morelli, M.P.; Cascone, T.; Troiani, T.; De Vita, F.; Orditura, M.; Laus, G.; Eckhardt, S.G.; Pepe, S.; Tortora, G.; Ciardiello, F. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16(Suppl 4), 61–68.
   Google Scholar
• Wang, Y.; Peng, D.; Huang, W.; Zhou, X.; Liu, J.; Fang, Y. Mechanism of altered TNF-alpha expression by macrophage and the modulatory effect of Panax notoginseng saponins in scald mice. Burns 2006, 32(7), 846–852.
   PubMed Web of Science ®Google Scholar
• Xu, J.M.; Paradiso, A.; McLeod, H.L. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: is there a need for a more rational design? Eur J Cancer 2004, 40(12), 1807–1809.
   PubMed Web of Science ®Google Scholar
• Baselga, J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004, 22, 759–761.
   PubMed Web of Science ®Google Scholar
• Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R.B.; Schiller, J.H; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J.S.; Averbuch, S.D.; Wolf, M.K.; Rennie, P.; Fandi, A.; Johnson, D.H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 2004, 22, 777–784.
   PubMed Web of Science ®Google Scholar
• Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J.A.; Wolf, M.K.; Krebs, A.D.; Averbuch, S.D.; Ochs, J.S.; Grous, J.; Fandi, A.; Johnson, D.H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 2004, 22, 785–794.
   PubMed Web of Science ®Google Scholar
• Herbst, R.S.; Prager, D.; Herman, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; Kris, M.G.; Tran, H.T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D.H.; Miller, V.A.; TRIBUTE Investigator Group. TRIBUTE—A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO 2004, 22, 7011.
   Google Scholar
• Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21, 2237–2246.
   PubMed Web of Science ®Google Scholar
• Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J., Jr.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290, 2149–2158.
   PubMed Web of Science ®Google Scholar
• Perez-Soler, R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small cell lung cancer. Clin Lung Cancer 2004, 6(Suppl 1), S20–S23.
   PubMedGoogle Scholar
• Xu, J.M.; Azzariti, A.; Colucci, G.; Paradiso, A. The effect of gefitinib in combination with oxaliplatin is schedule-dependent in colon cancer lines. Cancer Chemother Pharmacol 2003, 52, 442–448.
   PubMed Web of Science ®Google Scholar
• Azzariti, A.; Xu, J.M.; Porcelli, L.; Paradiso, A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004, 68(1), 135–144.
   PubMed Web of Science ®Google Scholar
• Jackisch, C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 2006, 11, 34–41.
   PubMed Web of Science ®Google Scholar
• Sauter, G.; Lee, J.; Bartlett, J.M.; Slamon, D.J.; Press, M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27(8), 1323–1333.
   PubMed Web of Science ®Google Scholar
• Hudziak, R.M.; Lewis, G.D.; Winget, M.; Fendly, B.M.; Shepard, H.M.; Ullrich, A. P185HER2 monoclonal antibody has antiproliferative effects in vivo and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989, 9(3), 1165–l172.
   PubMed Web of Science ®Google Scholar
• Goldenberg, M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999, 21(2), 309–318.
   PubMed Web of Science ®Google Scholar
• Chou, T.C. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008, 49(11), 2059–2080.
   PubMed Web of Science ®Google Scholar
• Xu, J.M.; Azzariti, A.; Severino, M.; Lu, B.; Colucci, G.; Paradiso, A. Characterization of sequence-dependent synergy between ZD1839 (“Iressa”) and oxaliplatin. Biochem Pharmacol 2003, 66(4), 551–563.
   PubMed Web of Science ®Google Scholar
• Pegram, M.D.; Lopez, A.; Konecny, G.; Slamon, D.J. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000, 27(6, Suppl 11), 21–25 (discussion 92–100).
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi, K.; Sekiguchi, F.; Tanaka, Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002, 49(3), 211–216.
   PubMed Web of Science ®Google Scholar
• Nahta, R.; Esteva, F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232(2), 123–138.
   PubMed Web of Science ®Google Scholar
• Knuefermann, C.; Lu, Y.; Liu, B.; Jin, W.; Liang, K.; Wu, L.; Schmidt, M.; Mills, G.B.; Mendelsohn, J.; Fan, Z. HER2/PI-3K/AKT activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22(21), 3205–3212.
   PubMed Web of Science ®Google Scholar
• Oki, E.; Baba, H.; Tokunaga, E.; Nakamura, T.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Maehara, Y. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117(3), 376–380.
   PubMed Web of Science ®Google Scholar
• Ozes, O.N.; Mayo, L.D.; Gustin, J.A.; Pfeffer, S.R.; Pfeffer, L.M.; Donner, D.B. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401(6748), 82–85.
   PubMed Web of Science ®Google Scholar
• Wang, W.; Cassidy, J. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer 2003, 88(4), 624–629.
   PubMed Web of Science ®Google Scholar
• Cummings, M.; Higginbottom, K.; McGurk, C.J.; Wong, O.G.; Köberle, B.; Oliver, R.T.; Masters, J.R. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006, 72(2), 166–175.
   PubMed Web of Science ®Google Scholar
• Peters, G.J.; Backus, H.H.; Freemantle, S.; van Triest, B.; Codacci-Pisanelli, G.; Van Der Wilt, C.L.; Smid, K.; Lunec, J.; Calvert, A.H.; Marsh, S.; McLeod, H.L.; Bloemena, E.; Meijer, S.; Jansen, G.; van Groeningen, C.J.; Pinedo, H.M. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002, 1587(2–3), 194–205.
   PubMed Web of Science ®Google Scholar
• Pietras, R.J.; Fendly, B.M.; Chazin, V.R.; Pegram, M.D.; Howell, S.B.; Slamon, D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9(7), 1829–1838.
   PubMed Web of Science ®Google Scholar